考虑诱导化疗反应的急性髓系白血病三因素动态生存模型
研究纳入759例接受强化治疗的急性髓系白血病(AML)患者,以诱导化疗是否达完全缓解(CR/CRi)为核心锚点,结合不良核型和年龄>55岁构建三因素生存模型并分为四层,各层中位生存(5年率)差异显著(p<.001),并在1032例外部队列中验证。
要点
- 未达CR/CRi(HR 3.8,95%CI 3.1-4.8)、不良核型(HR 2.2,95%CI 1.8-2.8)、年龄>55岁(HR 2.1,95%CI 1.6-2.7)为生存主要风险因素。
- 该模型分四层:低危0分(N=183)、中危-1 1分(N=331)、中危-2 2分(N=117)、高危≥3分(N=128)。
- 异基因造血干细胞移植(AHSCT)对生存有有利影响,在中危-1(p<.001)、中危-2(p=.03)、高危(p=.01)病中最明显。
核心结论
- 以诱导化疗反应为锚点的三因素生存模型可对强化治疗的AML患者进行四层风险分层,并可在外部队列中验证。
研究设计与样本
- 研究纳入759例接受强化治疗的急性髓系白血病(AML)非早幼粒细胞患者,中位年龄60岁。
- 原发66%、继发25%、治疗相关9%;欧洲白血病网细胞遗传学风险为有利8%、中间61%、不良31%。
- 该模型在1032例接受强化治疗的AML患者外部队列中验证。
主要发现
- 608例(80%)患者达完全缓解伴或不伴计数恢复(CR/CRi)。
- 中位随访22个月,记录503例死亡、272例复发和257例异基因造血干细胞移植(AHSCT)。
- 多因素分析显示未达CR/CRi(HR 3.8,95%CI 3.1-4.8)、不良核型(HR 2.2,95%CI 1.8-2.8)、年龄>55岁(HR 2.1,95%CI 1.6-2.7)为生存主要风险因素。
- 按HR加权评分分层:低危0分(N=183)、中危-1 1分(N=331)、中危-2 2分(N=117)、高危≥3分(N=128),各层中位生存(5年率)分别为未达到(68%)、34个月(37%)、13个月(20%)、5个月(5%),p<.001。
- FLT3-ITD突变与中危-1(p=.004)生存较差相关,TP53在中危-2(p=.06)和高危(p=.02)中相关;TP53的相关性完全由TP53突变与复杂/单体核型的密切关联解释,FLT3-ITD的观察结果不受米哚妥林治疗影响。
关键数值与推荐
- 风险评分:未达CR/CRi、不良核型、年龄>55岁各计1分,总分0分为低危、1分为中危-1、2分为中危-2、≥3分为高危。
临床怎么用
- AHSCT对生存有有利影响,在中危-1(p<.001)、中危-2(p=.03)、高危(p=.01)病中最明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The current study was approached with the assumption that response to induction chemotherapy, in acute myeloid leukemia (AML), overshadows pre-treatment risk variables in predicting survival and therefore be used as an anchor for a simplified risk model. We considered 759 intensively-treated patients with AML, not promyelocytic: median age 60 years; primary 66%, secondary 25%, and therapy-related 9%; European LeukemiaNet cytogenetic risk category favorable 8%, intermediate 61%, and adverse 31%. Complete remission with (CR) or without (CRi) count recovery was achieved in 608 (80%) patients. After a median follow-up of 22 months, 503 deaths, 272 relapses, and 257 allogeneic hematopoietic stem cell transplants (AHSCTs) were recorded. Multivariable analysis identified failure to achieve CR/CRi (HR 3.8, 95% CI 3.1-4.8), adverse karyotype (2.2, 1.8-2.8), and age >55 years (2.1, 1.6-2.7) as main risk factors for survival. HR-weighted scoring resulted in four-tiered risk stratification: low (0 points; N = 183), intermediate-1 (1 point; N = 331), intermediate-2 (2 points; N = 117), and high (≥3 points; N = 128), with respective median survival (5-year rate) not reached (68%), 34 (37%), 13 (20%), and 5 (5%) months (p < .001). FLT3-ITD mutation was associated with inferior survival in intermediate-1 (p = .004) and TP53 in intermediate-2 (p = .06) and high (p = .02) risk disease; the latter was fully accounted for by the close association between TP53 mutation and complex/monosomal karyotype while the observations regarding FLT3-ITD were not affected by treatment with midostaurin. AHSCT had a favorable impact on survival, most apparent in intermediate-1 (p < .001), intermediate-2 (p = .03), and high (p = .01) risk disease. The proposed 3-factor survival model offers a novel prototype that is amenable to further enhancement by molecular information and was validated in an external cohort of 1032 intensively-treated AML patients.
引用
- Tefferi A, Gangat N, Al-Kali A, et al. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol. 2022. PMID: 35702875. doi:10.1002/ajh.26630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。